Abstract
We examined the effects of atorvastatin on urinary podocyte excretion. Thirteen patients with type 2 diabetes receiving 2.5mg of rosuvastatin were recruited and the medication was switched to 10mg of atorvastatin for a 24-week period. With the switch to atorvastatin, the urinary excretion of podocytes was significantly reduced.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Atorvastatin
-
Biomarkers / blood
-
Biomarkers / urine
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / urine*
-
Diabetic Nephropathies / complications
-
Diabetic Nephropathies / drug therapy
-
Diabetic Nephropathies / urine*
-
Dyslipidemias / drug therapy
-
Dyslipidemias / etiology
-
Dyslipidemias / urine*
-
Female
-
Glycated Hemoglobin / metabolism
-
Heptanoic Acids / therapeutic use*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Male
-
Middle Aged
-
Oxidative Stress
-
Podocytes / drug effects*
-
Podocytes / metabolism
-
Pyrroles / therapeutic use*
Substances
-
Biomarkers
-
Glycated Hemoglobin A
-
Heptanoic Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrroles
-
hemoglobin A1c protein, human
-
Atorvastatin